Saturday 17 October 2026 Export INMD’s income statement to Excel — free account

InMode Ltd.

InMode Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $370.5 million, down 6.16% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 31.0% and free cash flow fell 12.6%, each against the same quarter a year earlier.

14.16 0.16 −1.12%

Follow INMD

Alert me

Market cap: $824.0M
P/E: 11.3×
Fwd P/E: 11.8×
Dividend yield: —
F-score: 4/9
Altman Z: 10.45
Beneish M: −2.25
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 18.31%

Capital & Financial Ratios $m

Market Cap 824.03

Revenue 374.63

Net Income 77.51

Free Cash Flow 82.53

Net Debt (501.11)

Current Ratio 8.18

Debt/Equity 0.00

P/E ratio 11.33

Fwd P/E 11.80

P/S ratio 2.23

P/B ratio 1.22

Past 5Y EPS Growth 9.95%

This Y EPS Growth (19.01%)

Next Y EPS Growth 5.84%

Next Y revenue growth (0.05%)

Next 5Y EPS Growth (3.28%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 39.99%

10-year low 10-year high

P/S against its own 10 years 1.05%

10-year low 10-year high

P/B against its own 10 years 0.44%

10-year low 10-year high

EV/Sales against its own 10 years 2.60%

10-year low 10-year high

EV/FCF against its own 10 years 11.34%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	742	596	555	501
Receivables	59	58	69	77
Inventory	45	60	74	72
Other	—	—	—	—
	845	714	699	650

	2023	2024	2025	Q'26
Payables	14	14	18	19
ST’ Debt	—	—	—	—
Other	50	56	53	61
	64	70	71	79

Compound Annual Growth %

	10y	5y	3y
Sales	—	12.44%	(6.57%)
Cash Flow	—	1.48%	(22.28%)
Earnings	—	4.57%	(16.56%)
Book Value	—	21.74%	7.20%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	82	96	—	—	—
’25	78	96	93	104	370
’24	80	86	130	98	395
’23	106	136	123	127	492
’22	86	114	121	134	454
’21	66	87	94	111	358
’20	40	31	60	75	206

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	15	21	—	—	—
’25	14	24	24	23	85
’24	24	42	34	32	133
’23	21	53	41	61	177
’22	32	47	46	57	182
’21	25	47	50	53	175
’20	6	1	30	42	79

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	15	21	—	—	—
’25	14	24	24	22	84
’24	24	42	34	32	132
’23	21	53	41	61	176
’22	32	46	45	57	180
’21	25	46	50	53	174
’20	6	1	30	42	79

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.18	0.29	—	—	—
’25	0.26	0.42	0.34	0.42	1.43
’24	0.28	0.28	0.65	1.14	2.25
’23	0.47	0.65	0.54	0.64	2.30
’22	0.36	0.52	0.58	0.44	1.89
’21	0.32	0.48	0.52	0.61	1.92
’20	0.08	0.11	0.29	0.43	0.89

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	6.53	6.57	22.65	20.60	18.57	14.87	13.14	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	29.38	26.60	99.27	71.03	48.25	26.80	19.78
People
People	Employees	—	—	209	251	311	362	480	581	599	660
	Revenue/emp, $m	—	0.00	0.48	0.62	0.66	0.99	0.95	0.85	0.66	0.56
Income, $m
Income, $m	Revenue	—	53	100	156	206	358	454	492	395	370
	Gross margin, %	—	83.06	84.97	87.06	85.03	85.01	83.82	83.60	80.31	78.54
	EBT	—	10	24	62	76	168	201	217	143	110
	EBT margin, %	—	18.33	23.59	39.68	36.94	46.99	44.35	44.16	36.34	29.78
	Net income	—	9	22	61	75	165	162	198	181	94
	Depreciation	—	0	0	0	0	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	1.02	1.88	2.67	2.86	4.39	5.51	5.89	4.98	5.73
	Earnings	—	0.17	0.42	1.05	1.04	2.03	1.96	2.37	2.29	1.45
	Cash flow	—	0.28	0.69	1.06	1.10	2.15	2.20	2.12	1.67	1.32
	Capex	—	0.00	(0.01)	(0.01)	(0.01)	(0.01)	(0.02)	(0.01)	(0.01)	(0.01)
	Free cash flow	—	0.27	0.69	1.05	1.09	2.14	2.18	2.11	1.66	1.30
	Book value	—	0.37	0.84	3.08	3.54	5.11	6.72	9.43	8.87	10.57
	Shares, m	—	53	53	58	72	81	82	84	79	65
Valuation, ×
Valuation, ×	P/E	—	10.66	10.66	18.95	23.27	35.11	17.99	9.34	7.05	10.06
	P/S	—	2.96	2.96	7.33	8.31	16.08	6.40	3.77	3.35	2.56
	P/B	—	6.62	6.62	6.37	6.70	13.82	5.24	2.36	1.88	1.39
	EV/Sales	—	2.29	2.29	6.09	7.04	14.91	5.20	2.27	1.84	1.06
	EV/FCF	—	7.59	7.59	15.48	18.43	30.66	13.12	6.33	5.51	4.68
Cash, $m
Cash, $m	Operating cash flow	—	15	37	62	79	175	182	177	133	85
	Capex	—	0	0	(1)	0	(1)	(2)	(1)	(1)	(1)
	Free cash flow	—	14	37	62	79	174	180	176	132	84
Balance, $m
Balance, $m	Working capital	—	24	48	181	255	418	547	781	645	628
	Total debt	—	—	—	1	1	5	5	—	—	—
	Net debt	—	(25)	(61)	(193)	(261)	(416)	(547)	(742)	(596)	(555)
	Shareholders’ equity	—	19	45	180	255	416	555	787	704	683
Returns, %
Returns, %	ROA	—	14.64	37.13	40.84	29.19	42.61	28.77	26.25	21.99	12.09
	ROIC	—	0.00	0.00	0.00	0.00	0.00	1,709.17	267.20	65.52	41.74
	ROE	—	28.12	69.77	54.48	34.47	49.15	33.29	29.50	24.31	13.53

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LMRI Lumexa Imaging Holdings, Inc.	$1.0B	— (loss-making)	14.2×	+7.82% (above 0%: growing)	n/m	+257.54% (above 0%: growing)	14.72%	8.72%	Compare
PRCT PROCEPT BioRobotics Corporation	$1.0B	— (loss-making)	— (loss-making)	+19.34% (above 0%: growing)	n/m	−24.43% (below 0%: shrinking)	66.01%	(28.98%)	Compare
QDEL QuidelOrtho Corporation	$953.9M	— (loss-making)	— (loss-making)	+2.77% (above 0%: growing)	n/m	−61.45% (below 0%: shrinking)	43.26%	(3.46%)	Compare
BBNX Beta Bionics, Inc.	$933.8M	— (loss-making)	— (loss-making)	+37.76% (above 0%: growing)	n/m	−1.87% (below 0%: shrinking)	59.04%	(79.90%)	Compare
SIBN SiBone	$892.3M	— (loss-making)	— (loss-making)	+15.18% (above 0%: growing)	n/m	+60.12% (above 0%: growing)	79.54%	(8.58%)	Compare
AHCO AdaptHealth Corp.	$871.2M	— (loss-making)	13.2×	+12.66% (above 0%: growing)	n/m	−128.56% (below 0%: shrinking)	14.08%	(18.61%)	Compare
INMD InMode Ltd.	$824.0M	11.3×	11.8×	−0.01% (below 0%: shrinking)	−30.95% (below 0%: shrinking)	−12.63% (below 0%: shrinking)	74.82%	12.82%
VREX VAREX IMAGING	$784.3M	34.7×	43.4×	+3.69% (above 0%: growing)	n/m	+757.14% (above 0%: growing)	36.44%	10.83%	Compare
CTKB Cytek Biosciences, Inc.	$703.2M	— (loss-making)	— (loss-making)	+5.57% (above 0%: growing)	n/m	+42.50% (above 0%: growing)	58.87%	(23.68%)	Compare
Median of peers	$913.1M	—	14.2×	+10.24%	—	+20.32%	51.07%	(13.59%)

All 149 Medical Devices stocks →

InMode Ltd. (INMD) key facts

Concern: InMode Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $370.5 million, down 6.16% from fiscal 2024.
InMode Ltd. (INMD) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, INMD traded at $14.16, a market capitalization of $824.0 million.
Return on equity was 13.5% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 10.45 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.